Abstract Heart failure is the final stage of various cardiovascular diseases.Cardiac stimulant,diuretic,vasodilators combined with sympathetic nerve inhibition and renin-angiotensin-aldosterone system inhibition are the means of clinical heart failure treating.To a certain extent,they delay the progression of heart failure.But the recurrence rate and mortality of heart failure patients are still very high.In recent years,with the widespread use of the diabetes drug-dapagliflozin,we have found that it can benefit patients with heart failure.Dapagliflozin was approved for the treatment of heart failure in February 2021 and has been widely used in clinical practice.A review of the latest research progress of the sodium glucose cotransporter-2 inhibitor dapagliflozin in the field of heart failure is presented.
[1] 中华医学会心血管病分学会心力衰竭组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789 [2] Guang H,Xin W,Zuo C,et al.Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey,2012-2015[J].European journal of heart failure,2019,21(11). [3] 国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组.2020中国心力衰竭医疗质量控制报告[J].中国循环杂志,2021,36(3):221-238.DOI:10.3969/ j.issn.1000-3614.2021.03.002. [4] Saisho Y.SGLT2 Inhibitors:the Star in the Treatment of Type 2 Diabetes[J].Disease,2020,8(2):14. [5] LYTVYN Y,BJORNSTAD P,UDELL J A,et al.Sodium glucose cotransporter-2 inhibition in heart failure:potential mechanismsSodium glucose cotransporter-2 inhibition in heart failure:potential mechanisms,clinical applications,and summary of clinical trials[J].Circulation,2017,136(17):1643-1658.DIO:10.1161/ CIRCULATIONAHA.117.030012. [6] Abdul Kadir,Clarke K,Evans RD.Cardiac ketone body metabolism[J].Biochimica et Biophysica Acta Molecular Basis of Dis.2020,1866(6):165739. [7] Li FF,Gao G,Li Q,Zhu HH,Su XF,Wu JD,Ye L,Ma JH,Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus[J].J Diabetes Res 2016;2016:5347262. [8] SHI L,ZHU D Q,WANG S B,et al.Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload[J].Am J Hypertens,2019,32(5):452-459.DOI:10.1093/ajh/hpz016. [9] Habibi J,Aroor AR,Sowers JR,et al.Sodium glucose transporter 2(SGLT2)inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.Cardiovasc Diabetol.2017;16:9.doi:10.1186/s12933-016-0489-z. [10] Yeve s A M,Ennis I L.Na+/H+exchanger and cardiac hypertrophy[J].Hipertens Riesgo Vasc,2020,37(1):22-32. [11] UTHMAN L,BAARTSCHEER A,BLEIJLEVENS B,et al.Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts:inhibition of Na+/H+exchanger,lowering of cytosolic Na+ and vasodilation[J].Diabetologia,2018,61(3):722-726.DOI:10.1007/s00125-017-4509-7. [12] 盛尔达. 钠-葡萄糖协同转运蛋白2抑制剂作用机制概述[J].糖尿病新世界,2021,24(24):190-193.DOI:10.16658/j.cnki.1672-4062.2021.24.190. [13] Yoshikawa T,Kishi T,Shinohara K,et al.Arterial pressure lability is improved by sodium -glucose cotransporter 2 inhibitor in streptozotocin -induced diabetic rats[J].Hyper tens Res,2017,40(7):646-651. [14] Zelniker T A,Bonaca M P,Furtado R H M,et al.Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus[J].Circulation,2020,141(15):1227-1234. [15] Uthman L,Homayr A,Juni R P,et al.Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor alpha-stimulated human coronary arterial endothelial cells[J].Cell Physiol Biochem,2019,53(5):865-886. [16] 张丽娜,王佳鑫,潘洪涛.早期应用达格列净在射血分数降低心力衰竭患者中的影响[J].中国卫生标准管理,2023,14(02):167-171. [17] 赵钟烈,谢扬.达格列净在危重症心力衰竭患者治疗中的应用效果分析[J].岭南急诊医学杂志,2022,27(06):555-557. [18] 孙浩栋,柳景文,周建华.(2023).基于心肺运动试验评价达格列净对HFpEF患者的临床治疗效果.实用药物与临床(05),422-427.doi:10.14053/j.cnki.ppcr.202305007. [19] 邓伏雪,王小娟,胡云凤,等.急性心肌梗死并发首次心力衰竭患者在院死亡率及临床预后分析[J].西安交通大学学报(医学版),2015,36(01):135-140. [20] 杨伊萍,周瑶瑶,施林军,等.达格列净治疗急性心肌梗死合并心力衰竭的疗效研究[J].中国现代医生,2023,61(25):100-104. [21] ZHANG N N,FENG B,MA X X,et al.Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J].Cardiovasc Diabetol,2019,18(1):107-122. [22] 王婧伟,王丽晓,吴寅莹.达格列净治疗糖尿病合并心力衰竭患者安全性和有效性的研究[J].黑龙江医药科学,2 022,45(05):62-63+66. [23] Mainak B,Indira M,Rimesh P,et al.Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure:a meta-analysis.[J].European heart journal,2023. [24] 吕华辉,邹祎,吕建平,等.达格列净联合螺内酯对糖尿病、非糖尿病心力衰竭患者的疗效[J].中国卫生标准管理,2023,14(19):132-136. [25] 沈祎玲,祁春梅.达格列净联合美托洛尔治疗2型糖尿病合并慢性心力衰竭的临床效果[J].中国医药,2022,17(12):1804-1808. [26] 孙杨,马博文.达格列净联合沙库巴曲缬沙坦钠治疗射血分数降低心力衰竭的临床效果[J].临床医学研究与实践,2023,8(28):46-49.DOI:10.19347/j.cnki.2096-1413.202328012. [27] 肖勇强,黄纪卫.(2023).达格列净联合左西孟旦治疗老年射血分数减低型心力衰竭患者的效果.?世界临床药物(05),477-482.doi:10.13683/j.wph.2023.05.012. [28] GAO YY,LIU LF,GAO L,et al.Effect of Qili Qiangxin Capsule combined with sacubitril/ valsartan on cardiac function in patients with chronic heart failure[J].Chin J Mod Appl Pharm,2020,37(20):2516-2520. [29] 唐敏,李丽燕.达格列净联合运动康复治疗2型糖尿病合并慢性心力衰竭的效果分析[J].中国社区医师,2023,39(21):48-50.
2024, Vol. 44 
